{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:04:00Z","timestamp":1794492240109,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01612-x","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T17:05:27Z","timestamp":1765559127000},"page":"741-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring New Dimensions in Longitudinal Rosacea Management"],"prefix":"10.1007","volume":"16","author":[{"given":"Martin","family":"Schaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Micali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dirschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz M. C.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0964-3357","authenticated-orcid":false,"given":"Khen","family":"Kon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"Bara\u0144ska-Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Dayrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"1612_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/bjd.18420","volume":"182","author":"M Schaller","year":"2020","unstructured":"Schaller M, Almeida LMC, Bewley A, et\u00a0al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182:1269\u201376.","journal-title":"Br J Dermatol"},{"key":"1612_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjd.15173","volume":"176","author":"M Schaller","year":"2017","unstructured":"Schaller M, Almeida LMC, Bewley A, et\u00a0al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:465\u201371.","journal-title":"Br J Dermatol"},{"key":"1612_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjd.15122","volume":"176","author":"J Tan","year":"2017","unstructured":"Tan J, Almeida LMC, Bewley A, et\u00a0al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:431\u20138.","journal-title":"Br J Dermatol"},{"key":"1612_CR4","first-page":"17","volume":"12","author":"JQ Del Rosso","year":"2019","unstructured":"Del Rosso JQ, Tanghetti E, Webster G, Stein Gold L, Thiboutot D, Gallo RL. Update on the management of rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol. 2019;12:17\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1612_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","volume":"78","author":"RL Gallo","year":"2018","unstructured":"Gallo RL, Granstein RD, Kang S, et\u00a0al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:148\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"1612_CR6","volume":"15","author":"M Schaller","year":"2022","unstructured":"Schaller M, Tan J, Webster G. How to optimize rosacea treatment for better patient outcomes: an opinion piece. J Clin Aesthet Dermatol. 2022;15:E60\u2013E62.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1612_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/der2.88","volume":"2","author":"J Tan","year":"2021","unstructured":"Tan J, Singh B, Song Y, et\u00a0al. Rosacea treatments: current standards and additional options. Dermatol Rev. 2021;2:357\u201378.","journal-title":"Dermatol Rev"},{"key":"1612_CR8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.2340\/00015555-2760","volume":"97","author":"K Lesner","year":"2017","unstructured":"Lesner K, Reich A, Szepietowski JC, et\u00a0al. Determinants of psychosocial health in psoriatic patients: a multi-national study. Acta Derm Venereol. 2017;97:1182\u20138.","journal-title":"Acta Derm Venereol"},{"key":"1612_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/09546634.2019.1623368","volume":"31","author":"J Tan","year":"2020","unstructured":"Tan J, Steinhoff M, Bewley A, Gieler U, Rives V. Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey. J Dermatol Treat. 2020;31:168\u201374.","journal-title":"J Dermatol Treat"},{"key":"1612_CR10","doi-asserted-by":"crossref","unstructured":"Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018;7:F1000 Faculty Rev-1885.","DOI":"10.12688\/f1000research.16537.1"},{"key":"1612_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.18773\/austprescr.2018.004","volume":"41","author":"AL Rivero","year":"2018","unstructured":"Rivero AL, Whitfeld M. An update on the treatment of rosacea. Aust Prescr. 2018;41:20\u20134.","journal-title":"Aust Prescr"},{"key":"1612_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jaad.2017.09.016","volume":"78","author":"R Haber","year":"2018","unstructured":"Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update. J Am Acad Dermatol. 2018;78:786\u201392.","journal-title":"J Am Acad Dermatol"},{"key":"1612_CR13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, et\u00a0al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1612_CR14","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1111\/jdv.14437","volume":"31","author":"M Schaller","year":"2017","unstructured":"Schaller M, Gonser L, Belge K, et\u00a0al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017;31:1907\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1612_CR15","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s12325-021-01624-x","volume":"38","author":"F-Y Wang","year":"2021","unstructured":"Wang F-Y, Chi C-C. Rosacea, germs, and bowels: a review on gastrointestinal comorbdities and gut-skin axis of rosacea. Adv Ther. 2021;38:1415\u201324.","journal-title":"Adv Ther"},{"key":"1612_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/CCID.S126850","volume":"11","author":"M Heisig","year":"2018","unstructured":"Heisig M, Reich A. Psychosocial aspects of rosacea with a focus on anxiety and depression. Clin Cosmet Investig Dermatol. 2018;11:103\u20137.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1612_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/j.1365-2133.2004.05985.x","volume":"150","author":"T Dirschka","year":"2004","unstructured":"Dirschka T, Tronnier H, F\u00f6lster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136\u201341.","journal-title":"Br J Dermatol"},{"key":"1612_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100031","volume":"1","author":"L Misery","year":"2021","unstructured":"Misery L. Irritated skin is not sensitive skin. JID Innov. 2021;1:100031.","journal-title":"JID Innov"},{"key":"1612_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jdv.16000","volume":"34","author":"L Misery","year":"2020","unstructured":"Misery L, Weisshaar E, Brenaut E, et\u00a0al. Pathophysiology and management of sensitive skin: position paper from the special interest group on sensitive skin of the International Forum for the Study of Itch (IFSI). J Eur Acad Dermatol Venereol. 2020;34:222\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1612_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2340\/00015555-1870","volume":"94","author":"L Misery","year":"2014","unstructured":"Misery L, Jean-Decoster C, Mery S, Georgescu V, Sibaud V. A new ten-item questionnaire for assessing sensitive skin: the Sensitive Scale-10. Acta Derm Venereol. 2014;94:635\u20139.","journal-title":"Acta Derm Venereol"},{"key":"1612_CR21","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.jaad.2018.08.049","volume":"80","author":"AF Alexis","year":"2019","unstructured":"Alexis AF, Callender VD, Baldwin HE, Desai SR, Rendon MI, Taylor SC. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019;80:1722\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1612_CR22","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1111\/jocd.14816","volume":"21","author":"A Sharma","year":"2022","unstructured":"Sharma A, Kroumpouzos G, Kassir M, et\u00a0al. Rosacea management: a comprehensive review. J Cosmet Dermatol. 2022;21:1895\u2013904.","journal-title":"J Cosmet Dermatol"},{"key":"1612_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1590\/abd1806-4841.20174485","volume":"92","author":"F Cabral","year":"2017","unstructured":"Cabral F, Lubbe LC, Martins N\u00f3brega M, Obadia DL, Souto R, Gripp AC. Morbihan disease: a therapeutic challenge. An Bras Dermatol. 2017;92:847\u201350.","journal-title":"An Bras Dermatol"},{"key":"1612_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.11622\/smedj.2018047","volume":"59","author":"WL Kok","year":"2018","unstructured":"Kok WL, Oon HH, Giam YC. A case report of granulomatous rosacea of the face. Singap Med J. 2018;59:228\u20139.","journal-title":"Singap Med J"},{"key":"1612_CR25","first-page":"241","volume":"3","author":"S Maden","year":"2023","unstructured":"Maden S. Rosacea: an overview of its etiological factors, pathogenesis, classification and therapy options. Dermatology. 2023;3:241\u201362.","journal-title":"Dermatology"},{"key":"1612_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1159\/000514565","volume":"7","author":"NE V\u00e1zquez-Herrera","year":"2021","unstructured":"V\u00e1zquez-Herrera NE, Zamora-Benze DM, Garz-Chapa JI, Rodr\u00edguez-Baca AB, Tosti A. Scalp rosacea: rethinking peripilar scaling. Skin Appendage Disord. 2021;7:382\u20136.","journal-title":"Skin Appendage Disord"},{"key":"1612_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1159\/000537807","volume":"10","author":"F Dall\u2019Oglio","year":"2024","unstructured":"Dall\u2019Oglio F, Nasca MR, Guglielmi G, Micali G. Scalp rosacea treated with topical ivermectin. Skin Appendage Disord. 2024;10:429\u201332.","journal-title":"Skin Appendage Disord"},{"key":"1612_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/archdermatol.2010.413","volume":"147","author":"TC Scharschmidt","year":"2011","unstructured":"Scharschmidt TC, Yost JM, Truong SV, Steinhoff M, Wang C, Berger TG. Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment. Arch Dermatol. 2011;147:123\u20136.","journal-title":"Arch Dermatol"},{"key":"1612_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/1346-8138.15629","volume":"48","author":"HO Kim","year":"2021","unstructured":"Kim HO, Kang SY, Kim KE, Cho SY, Kim KH, Kim IH. Neurogenic rosacea in Korea. J Dermatol. 2021;48:49\u201355.","journal-title":"J Dermatol"},{"key":"1612_CR30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/jdv.14885","volume":"32","author":"FMN Forton","year":"2018","unstructured":"Forton FMN, De Maertelaer V. Papulopustular rosacea and rosacea-like demodicosis: two phenotypes of the same disease? J Eur Acad Dermatol Venereol. 2018;32:1011\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1612_CR31","first-page":"420","volume":"179","author":"N Lacey","year":"2018","unstructured":"Lacey N, Russel-Hallinan A, Zouboulis CC, Powell FC. Demodex mites modulate sebocyte immune reaction: possible role in the pathogenesis of rosacea. Br J Dermatol. 2018;179:420\u201330.","journal-title":"Br J Dermatol"},{"key":"1612_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjd.13783","volume":"173","author":"EC Sattler","year":"2015","unstructured":"Sattler EC, Hoffmann VS, Ruzicka T, Braunm\u00fchl TV, Berking C. Reflectance confocal microscopy for monitoring the density of Demodex mites in patients with rosacea before and after treatment. Br J Dermatol. 2015;173:69\u201375.","journal-title":"Br J Dermatol"},{"key":"1612_CR33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/jocd.13082","volume":"19","author":"H-P Huang","year":"2020","unstructured":"Huang H-P, Hsu C-K, Lee JY-Y. A new superficial needle-scraping method for assessing Demodex density in papulopustular rosacea. J Cosmet Dermatol. 2020;19:896\u2013900.","journal-title":"J Cosmet Dermatol"},{"key":"1612_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/DAD.0000000000000454","volume":"38","author":"WJ Lee","year":"2016","unstructured":"Lee WJ, Jung JM, Lee YJ, et\u00a0al. Histopathological analysis of 226 patients with rosacea according to rosacea subtype and severity. Am J Dermatopathol. 2016;38:347\u201352.","journal-title":"Am J Dermatopathol"},{"key":"1612_CR35","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jaad.2020.01.077","volume":"82","author":"D Thiboutot","year":"2020","unstructured":"Thiboutot D, Anderson R, Cook-Bolden F, et\u00a0al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82:1501\u201310.","journal-title":"J Am Acad Dermatol"},{"key":"1612_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010115","volume":"12","author":"D Nowicka","year":"2022","unstructured":"Nowicka D, Chilicka K, Dzie\u0144dziora-Urbi\u0144ska I, Szygu\u0142a R. Skincare in rosacea from the cosmetologist\u2019s perspective: a narrative review. J Clin Med. 2022;12:115.","journal-title":"J Clin Med"},{"key":"1612_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/jocd.15519","volume":"22","author":"CL Goh","year":"2023","unstructured":"Goh CL, Wu Y, Welsh B, et\u00a0al. Expert consensus on holistic skin care routine: focus on acne, rosacea, atopic dermatitis, and sensitive skin syndrome. J Cosmet Dermatol. 2023;22:45\u201354.","journal-title":"J Cosmet Dermatol"},{"key":"1612_CR38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.36849\/JDD.5861","volume":"20","author":"H Baldwin","year":"2021","unstructured":"Baldwin H, Alexis AF, Andriessen A, et\u00a0al. Evidence of barrier deficiency in rosacea and the importance of integrating OTC skincare products into treatment regimens. J Drugs Dermatol. 2021;20:384\u201392.","journal-title":"J Drugs Dermatol"},{"key":"1612_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030411","volume":"15","author":"M Manfredini","year":"2025","unstructured":"Manfredini M, Barbieri M, Milandri M, Longo C. Probiotics and diet in rosacea: current evidence and future perspectives. Biomolecules. 2025;15:411. https:\/\/doi.org\/10.3390\/biom15030411.","journal-title":"Biomolecules"},{"key":"1612_CR40","first-page":"34","volume":"16","author":"ND Bhatia","year":"2023","unstructured":"Bhatia ND, Werschler WM, Baldwin H, et\u00a0al. Efficacy and safety of microencapsulated benzoyl perozide cream, 5%, in rosacea: results from two Phase III, randomised, vehicle-controlled trials. J Clin Aesthet Dermatol. 2023;16:34\u201340.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1612_CR41","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jaad.2020.01.043","volume":"82","author":"L Stein Gold","year":"2020","unstructured":"Stein Gold L, Del Rosso JQ, Kircik LH, et\u00a0al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82:1166\u201373.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 6","key":"1612_CR42","first-page":"17","volume":"14","author":"M Schaller","year":"2016","unstructured":"Schaller M, Sch\u00f6fer H, Homey B, et\u00a0al. Rosacea management: update on general measures and topical treatment options. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2016;14(Suppl 6):17\u201327.","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"1612_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15180","volume":"35","author":"JQ Del Rosso","year":"2022","unstructured":"Del Rosso JQ, Brantman S, Baldwin H. Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily. Dermatol Ther. 2022;35:e15180.","journal-title":"Dermatol Ther"},{"key":"1612_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.annder.2021.11.001","volume":"149","author":"B Cribier","year":"2022","unstructured":"Cribier B. Rosacea: treatment targets based on new physiopathology data. Ann Dermatol Venereol. 2022;149:99\u2013107.","journal-title":"Ann Dermatol Venereol"},{"key":"1612_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40268-016-0141-0","volume":"16","author":"M Schaller","year":"2016","unstructured":"Schaller M, Gonser L. A tailored approach to the treatment of a patient with a severe dynamic manifestation of rosacea: a case report. Drugs R D. 2016;16:279\u201383.","journal-title":"Drugs R D"},{"key":"1612_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15869","volume":"35","author":"M Schaller","year":"2022","unstructured":"Schaller M, Riel S, Bashur R, Kurup N, Schnidar H, Fehrenbacher B. Ivermectin treatment in rosacea: how novel smartphone technology can support monitoring rosacea-associated signs and symptoms. Dermatol Ther. 2022;35:e15869.","journal-title":"Dermatol Ther"},{"key":"1612_CR47","first-page":"1380","volume":"13","author":"L Stein Gold","year":"2014","unstructured":"Stein Gold L, Kircik L, Fowler J, et\u00a0al. Long-term safety of ivermectin 1% cream vs azeliac acid 15% gel in treating inflammatory lesion of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13:1380\u20136.","journal-title":"J Drugs Dermatol"},{"key":"1612_CR48","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jaad.2018.01.027","volume":"78","author":"ZD Draelos","year":"2018","unstructured":"Draelos ZD, Gold MH, Weiss RA, et\u00a0al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78:1156\u201363.","journal-title":"J Am Acad Dermatol"},{"key":"1612_CR49","first-page":"32","volume":"14","author":"JQ Del Rosso","year":"2021","unstructured":"Del Rosso JQ, Tanghetti E. Topical oxymetazoline hydrochloride cream 1% for the treatment of persistent facial erythema of rosacea in adults: a comprehensive review of current evidence. J Clin Aesthet Dermatol. 2021;14:32\u20137.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1612_CR50","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2147\/PPA.S115708","volume":"11","author":"MS Anderson","year":"2017","unstructured":"Anderson MS, Nadkarni A, Cardwell LA, Alinia H, Feldman SR. Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability. Patient Prefer Adher. 2017;11:1143\u201350.","journal-title":"Patient Prefer Adher"},{"key":"1612_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.58600\/eurjther-346","volume":"29","author":"A Ataseven","year":"2023","unstructured":"Ataseven A, Temiz SA, \u00d6zer I. An investigation of the effectiveness of the 577-nm pro-yellow laser in patients with vascular disorders. Eur J Ther. 2023;29:49\u201354.","journal-title":"Eur J Ther"},{"key":"1612_CR52","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jocd.14085","volume":"21","author":"SA Temiz","year":"2021","unstructured":"Temiz SA, Durmaz K, I\u015f\u0131k B, Ataseven A, Dursun R. The effect of 577-nm pro-yellow laser on demodex density in patients with rosacea. J Cosmet Dermatol. 2021;21:242\u20136.","journal-title":"J Cosmet Dermatol"},{"key":"1612_CR53","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/ijd.16920","volume":"63","author":"LMC Almeida","year":"2024","unstructured":"Almeida LMC, Ianhez M, Dal\u2019Forno T, et\u00a0al. Long-term maintenance treatment of rosacea: experts opinion. Int J Dermatol. 2024;63:94\u2013101.","journal-title":"Int J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01612-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01612-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01612-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:02:40Z","timestamp":1772006560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01612-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01612-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Martin Schaller reports grants and personal fees from Galderma, personal fees from Abbvie, personal fees from Bayer Healthcare, personal fees from InfectoPharm, personal fees from Lilly, outside of the submitted work. Belinda Welsh reports advisory and speaker roles for Galderma and Candela. Giuseppe Micali reports advisory speaker roles for Eli Lilly, UCB, Pfizer and Incyte. Jerry Tan reports advisory, consultant and speaker roles for Avene, Bausch, Boots Walgreens, Galderma, L\u2019Oreal and Sun Pharma. James Del Rosso reports clinical research investigator*, consultancy\/ advisory^ and speaker\n                      #\n                      roles for AbbVie^\n                      #\n                      , Aclaris*^\n                      #\n                      , Almirall*, Amgen (Celgene)*^\n                      #\n                      , Anaptys Bio*, Apogee Therapeutics*, Arcutis*^, Aslan*^, Athenex*, Bausch (Ortho Dermatology)*^\n                      #\n                      , Beiersdorf^\n                      #\n                      , Biofrontera^*, Biopharmx*^, Biorasi*, Blue Creek^, Botanix*, Bristol Myers Squibb*^\n                      #\n                      , Cage Bio*, Cara Therapeutics*, Cassiopea*^, Dermata^ Dermavant^*, Encore^*, EPI Health*^\n                      #\n                      , Evommune*^, Ferndale^*, Galderma*^\n                      #\n                      , Genentech*\n                      #\n                      ,Incyte*^\n                      #\n                      , Janssen*, Johnson & Johnson^, La Roche Posay^, LEO Pharma*^\n                      #\n                      , Lilly*^\n                      #\n                      , L\u2019Or\u00e9al^, MC2^, Moonlake*, Nektar*, Novan *^, Nutrafol^, Pfizer*^\n                      #\n                      , Ralexar*, RBC Consultants^, Regeneron*^\n                      #\n                      , Sanofi-Genzyme^*, Sente^, Solgel*^, Sonoma (Intraderm)^, Sun Pharma*^\n                      #\n                      , Takeda*^, UCB*^\n                      #\n                      , Verrica^* and Vyne\n                      #\n                      . Julie Harper reports advisory and speaker roles for Almirall, Arcutis Biotherapeutics, Bioderma, Beiersdorf, Bubble Beauty Inc, Cutera, Galderma, Journey Medical Corporation, L\u2019Or\u00e9al, Nutrafol, Ortho Dermatologics, Pelthos Therapeutics, Sagimet Biosciences, Sanofi and Sun Pharma. Thomas Dirschka reports research support for Abbvie, Almirall,\u00a0Biofrontera, Damae, Emblation, Galderma, Intros, ISDIN, La Roche Posay,\u00a0L \u2018\u00d3real, Mylan, Nordberg,\u00a0Olistic, Schulze &\u00a0B\u00f6hm\u00a0GmbH,\u00a0Scibase\u00a0S.A.,\u00a0Smartinmedia AG, Speclipse, and Vichy. Lectures for Aesclepion, Almirall,\u00a0Biofrontera,\u00a0Damae,\u00a0Dr.\u00a0August Wolff, Galderma, GSK,\u00a0Infectopharm, Intros, Janssen-Cilag, Leo, Louis Widmer, Mylan, Neracare, Nordberg, Novartis, Pierre Fabre, Pfizer,\u00a0Riemser,\u00a0Speclipse, and UCB. Member of advisory boards for Almirall, Beiersdorf,\u00a0Biofrontera, GSK,\u00a0Dr.\u00a0Pfleger, Galderma, Janssen-Cilag, Leo, Mylan,\u00a0Neracare, Nordberg, Novartis, Pierre Fabre,\u00a0Scibase,\u00a0Smart In Media AG, and Vichy. Soyun Cho has nothing to disclose. Luiz MC Almeida has nothing to disclose. Wioletta Bara\u0144ska-Rybak reports advisory and speaker roles for Galderma. Johannes Dayrit reports speaker roles for Isispharma. Linda Stein Gold reports advisory, investigator and speaker roles for Galderma, Almirall, Journey Medical Corporation, Ortho Dermatologics and Sun Pharma. Khen Kon is an employee of Galderma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not involve any new studies with human participants or animals conducted by the authors. Written informed consent was obtained from all patients featured in the clinical case studies for the publication of any potentially identifiable data or images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This framework was conceived and developed by the Rosacea\u2013Expert Advice on Combined and Holistic approaches (REACH) Global Scientific Committee (GSC) across three meetings, which included Martin Schaller, Belinda Welsh, Giuseppe Micali, Jerry Tan, James Del Rosso, Julie Harper, Thomas Dirschka, Soyun Cho, Luiz MC Almeida, Wioletta Bara\u0144ska-Rybak, Johannes Dayrit, and Linda Stein Gold.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conception Statement"}}]}}